Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients

Table 3 Demographic characteristics

Parameter^a	Cyclosporine + MMF	Tacrolimus + EC-MPS	P value
	(n = 30)	(n = 28)
Age (years)	52.3 ± 9.29	54.1 ± 11.5	0.527^b
Time post-transplant (years)	6.93 ± 4.27	5.15 ± 3.34	0.084^b
Male	30 (100%)	13 (46.4%)	<0.001*
Caucasian	17 (56.7%)	13 (46.4%)	0.221^c
BMI (kg/m²)	33.1 ± 6.73	30.4 ± 6.94	0.151^b
eGFR (ml/min/1.73 m²)	51.7 ± 13.5	52.2 ± 18.7	0.921^b
Albumin	4.24 ± 0.37	4.26 ± 0.41	0.839^b
WBC (cells/mm³)	6.81 ± 2.26	6.38 ± 1.52	0.401^b
MPA dose^e	1417 ± 407	1242 ± 319	0.048^d*
Prednisone use	12 (40.0%)	9 (32.1%)	0.585 ^c
Calcineurin inhibitor trough concentration (ng/ml)	124 ± 47.1	6.80 ± 1.98	NA

^aData presented as mean ± standard deviation or frequency (percentage); ^bT test; ^c Chi-square test; ^dWilcoxon test; ^eExpressed as active mycophenolic acid.
*p ≤ 0.05: statistical significance.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid; EC-MPS, enteric coated mycophenolate sodium; NA, not applicable; WBC, white blood cells.

ISSN: 1471-2369